MANF is too pre-clinical my friend. For now, we are about LymPro. But Lympro is not nearly as valuable now as it will be a year or two from now.

I say Gerald spins off the diagnostic division to existing shareholders first....and then a sale of that division might happen down the road.

MANF orphan will help our value a bit, but we won't see big MANF value for a couple more years!!

LymPro$$$$$LymPro$$$$LymPro$$$$